medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 2

<< Back Next >>

Ann Hepatol 2016; 15 (2)

IL-1β siRNA adenovirus benefits liver regeneration by improving mesenchymal stem cells survival after acute liver failure

Ma H, Shi X, Yuan X, Ding Y

Language: English
References: 37
Page: 260-270
PDF size: 284.72 Kb.


ABSTRACT

Background: Uncontrolled hapatic inflammatory response is regarded as the primary pathological mechanism of acute liver failure and impairs the regeneration of hepatocytes and stem cell grafts. Interleukin-1 plays a key role for activating immune and inflammatory response. Recently, siRNA has made quite a few progresses in treating inflammatory response. Aim. To assess the effect of IL-1β siRNA adenovirus on MSC and the therapeutic effect of MSC combined with IL-1β siRNA adenovirus in ALF. Material and methods. We implanted MSC or/and IL-1β siRNA adenovirus via the tail vein, using CCl4-induced ALF in a mice model. Mice were sacrificed at different time points. Blood samples and liver tissues were collected. Hepatic injury, liver regeneration, cytokines (CXCL1, IL-1β, IL-10, IL-6, VEGF and HGF), animal survival and vital MSC were assessed after cell transplantation. Results. MSC combined with IL-1β siRNA reduced the inflammatory levels and prevented liver failure. These animals administrated with MSC and IL-1β siRNA also exhibited improved liver regeneration and increased survival rates. Immunohistochemistry and fluorescence microscopy revealed the number of vital MSC in ALF + MSC + IL-1β siRNA group were significantly more than that in ALF + MSC group. Conclusion. IL-1β siRNA adenovirus could enhance MSC ability of tissue regeneration through increasing its survival rate. Accordingly, combination of IL-1β siRNA adenovirus and MSC had a synergistic effect on acute liver failure.


REFERENCES

  1. Krysko DV, Denecker G, Festjens N, Gabriels S, Parthoens E, D’Herde K, Vandenabeele P. Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ 2006; 13: 2011-22.

  2. Leifeld L, Dumoulin FL, Purr I, Janberg K, Trautwein C, Wolff M, Manns MP, et al. Early upregulation of chemokine expression in fulminant hepatic failure. J Pathol 2003; 199: 335-44.

  3. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-36.

  4. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. Stem Cells 2007; 25: 2896-902.

  5. Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, et al. Bone marrow as a potential source of hepatic oval cells. Science 1999; 284: 1168-70.

  6. Moore JK, Stutchfield BM, Forbes SJ. Systematic review: the effects of autologous stem cell therapy for patients with liver disease. Aliment Pharmacol Ther 2014; 39: 673-85.

  7. Levine P, McDaniel K, Francis H, Kennedy L, Alpini G, Meng F. Molecular mechanisms of stem cell therapy in alcoholic liver disease. Dig Liver Dis 2014; 46: 391-7.

  8. Salomone F, Barbagallo I, Puzzo L, Piazza C, Li Volti G. Efficacy of adipose tissue-mesenchymal stem cell transplantation in rats with acetaminophen liverinjury. Stem Cell Res 2013; 11: 1037-44.

  9. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM, Rameshwar P. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107: 4817-24.

  10. Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X, Yang R, et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med 2011; 17: 1594-601.

  11. Dang S, Xu H, Xu C, Cai W, Li Q, Cheng Y, Jin M, et al. Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmuneencephalomyelitis. Autophagy 2014; 10: 1301-15.

  12. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007; 104: 11002-07.

  13. Girard S, Kadhim H, Larouche A, Roy M, Gobeil F, Sébire G. Pro-inflammatory disequilibrium of the IL-1 beta/IL-1ra ratio in an experimental model of perinatal brain damages induced by lipopolysaccharide and hypoxia-ischemia. Cytokine 2008; 43: 54-62.

  14. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: iii2-iii9.

  15. Tron K, Novosyadlyy R, Dudas J, Samoylenko A, Kietzmann T, Ramadori G. Upregulation of heme oxygenase-1 gene by turpentine oil-induced localized inflammation: involvement ofinterleukin-6. Lab Invest 2005; 85: 376-87.

  16. Xiao JQ, Shi XL, Ma HC, Tan JJ, Lin-zhang, Xu Q, Ding YT. Administration of IL-1Ra chitosan nanoparticles enhances the therapeutic efficacy of mesenchymal stem cell transplantation in acute liver failure. Arch Med Res 2013; 44: 370-9.

  17. Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007; 117: 3615-22.

  18. Kawakami S, Hashida M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007; 22: 142-51.

  19. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007; 59: 164-82.

  20. Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005; 12: 5-11.

  21. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-51.

  22. Saito Y, Kon S, Fujiwara Y, Nakayama Y, Kurotaki D, Fukuda N, Kimura C, et al. Osteopontin small interfering RNA protects mice from fulminant hepatitis. Hum Gene Ther 2007; 18: 1205-14.

  23. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 2007; 28: 1434-42.

  24. Kitano Y, Radu A, Shaaban A, Flake AW. Selection, enrichment, and culture expansion of murine mesenchymal progenitor cells by retroviral transduction of cycling adherent bone marrow cells. Exp Hematol 2000; 28: 1460-9.

  25. Shi XL, Zhu W, Tan JJ, et al. Effect evaluation of interleukin-1 receptor antagonist nanoparticles for mesenchymal stem cell transplantation. World J Gastroenterol 2013; 19: p1984- p1991.

  26. Zheng YB, Zhang XH, Huang ZL, Lin CS, Lai J, Gu YR, Lin BL, et al. Amniotic-fluid-derived mesenchymal stem cells overexpressing interleukin-1 receptor antagonist improvefulminant hepatic failure. PLoS One 2012; 7: e41392.

  27. Foged C. siRNA delivery with lipid-based systems: promises and pitfalls. Curr Top Med Chem 2012; 12: 97-107.

  28. Gooding M, Browne LP, Quinteiro FM, Selwood DL. siRNA delivery: from lipids to cell-penetrating peptides and their mimics. Chem Biol Drug Des 2012; 80:787-809.

  29. Mizuguchi Y, Yokomuro S, Mishima T, Arima Y, Shimizu T, Kawahigashi Y, Kanda T, et al. Short hairpin RNA modulates transforming growth factor beta signaling in life-threatening liver failure in mice. Gastroenterology 2005; 129: 1654-62.

  30. Liu MS, Zhao ZF, Wang L, Zhang GY, Zhang Y, Yang H, Qiao JG, et al. Recombinant adenovirus vector with Fas(CD95)-targeted shRNAs inhibited LPS-inducing Fas overexpression of mouse hepatoeytes. Zhonghua Ganzangbing Zazhi 2007; 15: 475-76.

  31. Jiang N, Zhang X, Zheng X, Chen D, Siu K, Wang H, Ichim TE, et al. A Novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLoS One 2012; 7: e44138.

  32. Koppers-Lalic D, Hogenboom MM, Middeldorp JM, Pegtel DM. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv Drug Deliv Rev 2013; 65: 348-56.

  33. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169: 12-20.

  34. Hu-Cheng Ma, Xiao-Lei Shi, Hao-Zhen Ren, Xian-Wen Yuan, Yi-Tao Ding. Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liverregeneration. World J Gastroenterol 2014; 20: 14884-94.

  35. Salama H, Zekri AR, Medhat E, Al Alim SA, Ahmed OS, Bahnassy AA, Lotfy MM, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther 2014; 5: 70.

  36. Spahr L, Chalandon Y, Terraz S, Kindler V, Rubbia-Brandt L, Frossard JL, Breguet R, et al. Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS One 2013; 8: e53719.

  37. Xu L, Gong Y, Wang B, Shi K, Hou Y, Wang L, Lin Z, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. J Gastroenterol Hepatol 2014; 29: 1620-8.




2020     |     www.medigraphic.com